Author: Lucy J. Sannes, PhD, MBA
TABLES
Table 2.1. FDA-Approved Drugs for Treatment of Alzheimer’s Disease 9
Table 2.2. Selected Companies Developing Immunotherapies (Monoclonal Antibodies or Vaccines) for Treatment of Alzheimer’s Disease 13
Table 3.1. FDA-Approved Drugs for Use as an Aid in Smoking Cessation 34
Table 3.2. Selected Companies Developing Vaccines for Treatment of Cocaine Addiction or Nicotine Addiction (Smoking Cessation) 37
Table 4.1. Selected Non-Opioid Analgesics 49
Table 4.2. Selected Opioid Analgesics 55
Table 4.3. Selected Companies Developing and/or Marketing Immunotherapies (Antibodies, Antibody-Derived Agents, or Vaccines) for Other Neurology Applications 60
Table 5.1. Selected Heart/Cardiovascular Drugs Including Lipid-Lowering Drugs and Drugs for Treatment of Hypertension 77
Table 5.2. Selected Companies Developing and/or Marketing Immunotherapies (Antibodies, Antibody-Derived Agents, or Vaccines) for Cardiovascular Diseases 96
Table 6.1. FDA-Approved Immune Globulin Intravenous (IGIV) Preparations and Their Indications 102
Table 6.2. FDA-Approved Rho(D) Immune Globulin and Immune Globulin Intravenous Preparations 104
Table 6.3. Current Non-Immune Globulin Therapies for Selected Hematology Indications 105
Table 6.4. Emerging Immunotherapies for Treatment of Hematology/Blood Disorders 109
Table 7.1. Current Pharmacological Therapies for Wet Age-Related Macular Degeneration 119
Table 7.2. Emerging Antibody-Based Therapies for Ophthalmic Diseases 124
Table 8.1. FDA-Approved Drugs for Prevention and Treatment of Osteoporosis 130
Table 8.2. Emerging Antibodies and Antibody-Derived Therapies for Osteoporosis and Other Bone Metabolism Disorders 135
Table 9.1. FDA-Approved Drugs for Treatment of Type 2 Diabetes 143
Table 9.2. Emerging Monoclonal Antibodies for Treatment of Type 2 Diabetes 147
Table 10.1. Emerging Antibodies, Antibody-Based Drugs, and Anti-inflammatory Drugs for Selected Other Indications 153
FIGURES
Figure 11.1. Nanobody Formatting—A Major Advantage 174
Figure 11.2. The Value of Formatting For Receptor Binding 175